Association between IL-33 Gene Polymorphisms (rs1929992, rs7044343) and Systemic Lupus Erythematosus in a Chinese Han Population

References

• Brint EK, Fitzgerald KA, Smith P, et al. (2002). Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction. J Biol Chem, 277, 49205–11.
   PubMed Web of Science ®Google Scholar
• Brugos B, Vincze Z, Sipka S, et al. (2012). Serum and urinary cytokine levels of SLE patients. Pharmazie, 67, 411–3.
   PubMed Web of Science ®Google Scholar
• Carneiro JR, Fuzii HT, Kayser C, et al. (2011). IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics (Sao Paulo), 66, 77–82.
   PubMed Web of Science ®Google Scholar
• Chackerian AA, Oldham ER, Murphy EE, et al. (2007). IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol, 179, 2551–5.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Lin KH, Lin SC, et al. (2005). High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol, 32, 44–7.
   PubMed Web of Science ®Google Scholar
• Chen GM, Feng CC, Ye QL, et al. (2013). Association of P2X7R gene polymorphisms with systemic lupus erythematosus in a Chinese population. Mutagenesis, 28, 351–5.
   PubMed Web of Science ®Google Scholar
• Churg J, Bernstein J, Glassock RJ. (1995). Renal disease classification and atlas of glomerular disease, second edition. Ann Intern Med, 123, 4–5.
   Google Scholar
• Dupont WD, WD Plummer Jr. (1990). Power and sample size calculations. A review and computer program. Control Clin Trials, 11, 116–28.
   PubMedGoogle Scholar
• Fan D, Ding N, Yang T, et al. (2014). Single nucleotide polymorphisms of the interleukin-33 (IL-33) gene are associated with ankylosing spondylitis inChinese individuals: a case-control pilot study. Scand J Rheumatol, 43, 374–9.
   PubMed Web of Science ®Google Scholar
• Han GW, Zeng LW, Liang CX, et al. (2011). Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol, 30, 1583–8.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1725.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Baek SY, Park MK, et al. (2013). Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet’s disease. J Korean Med Sci, 28, 1145–53.
   PubMed Web of Science ®Google Scholar
• Koca SS, Kara M, Deniz F, et al. (2015). Serum IL-33 level and IL-33 gene polymorphisms in Behçet’s disease. Rheumatol Int, 35, 471–7.
   PubMed Web of Science ®Google Scholar
• Kurowska-Stolarska M, Hueber A, Stolarski B, et al. (2011). Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med, 269, 29–35.
   PubMed Web of Science ®Google Scholar
• Li C, Mu R, Guo J, et al. (2014). Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther, 16, R105.
   PubMed Web of Science ®Google Scholar
• Li P, Lin W, Zheng X. (2014). IL-33 neutralization suppresses lupus disease in lupus-prone mice. Inflammation, 37, 824–32
   PubMed Web of Science ®Google Scholar
• Liu J, Liu J, Ni J, et al. (2015). Association of UBASH3A gene polymorphisms and systemic lupus erythematosus in a Chinese population. Gene, 565, 116–21.
   PubMed Web of Science ®Google Scholar
• McLaren JE, Michael DR, Salter RC, et al. (2010). IL-33 reduces macrophage foam cell formation. J Immunol, 185, 1222–9.
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, et al. (2008). IL-33 reduces the development of atherosclerosis. J Exp Med, 205, 339–46.
   PubMed Web of Science ®Google Scholar
• Moulin D, Donzé O, Talabot-Ayer D, et al. (2007). Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine, 40, 216–25.
   PubMed Web of Science ®Google Scholar
• Ni J, Liu J, Leng RX, et al. (2016). Genetic Polymorphism (rs329498) in the Pellino-1 Gene as Possible Predisposal Factor for Systemic Lupus Erythematosus in a Chinese Population. Immunol Invest, 45, 181–90.
   PubMed Web of Science ®Google Scholar
• Palafox-Sánchez CA, Oregon-Romero E, Salazar-Camarena DC, et al. (2015). Association of interleukin-10 promoter haplotypes with disease susceptibility and IL-10 levels in Mexican patients with systemic lupus erythematosus. Clin Exp Med, 15, 439–46.
   PubMed Web of Science ®Google Scholar
• Samarkos M, Davies KA, Gordon C, et al. (2006). Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol, 25, 199–204.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23, 479–90.
   PubMed Web of Science ®Google Scholar
• Shahin RM, El Khateeb E, Khalifa RH, et al. (2016). Contribution of Toll-Like Receptor 9 Gene Single-Nucleotide Polymorphism to Systemic Lupus Erythematosus in Egyptian Patients. Immunol Invest, 45, 235–42.
   PubMed Web of Science ®Google Scholar
• Suzukawa M, Koketsu R, Iikura M, et al. (2008). Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest, 88, 1245–53.
   PubMed Web of Science ®Google Scholar
• Tang S, Huang H, Hu F, et al. (2013). Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis. Clin Dev Immunol, 2013, 985301.
   PubMedGoogle Scholar
• Xu D, Jiang HR, Kewin P, et al. (2008). IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A, 105, 10913–8.
   PubMed Web of Science ®Google Scholar
• Xu WD, Pan HF, Xu Y, et al. (2013). Interferon regulatory factor 5 and autoimmune lupus. Expert Rev Mol Med, 15, e6.
   PubMed Web of Science ®Google Scholar
• Xu WD, Peng H, Zhou M, et al. (2013). Association of RANTES and MBL gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Mol Biol Rep, 40, 941–8.
   PubMed Web of Science ®Google Scholar
• Xu WD, Zhang M, Zhang YJ, et al. (2013). IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy. Hum Immunol, 74, 1057–60.
   PubMed Web of Science ®Google Scholar
• Yang Z, Liang Y, Xi W, et al. (2011). Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupuserythematosus in Chinese population. Clin Exp Med, 11, 75–80.
   PubMed Web of Science ®Google Scholar
• Yuan FL, Li X, Lu WG, et al. (2011). IL-33: a promising therapeutic target for rheumatoid arthritis? Expert Opin Ther Targets, 15, 529–34.
   PubMed Web of Science ®Google Scholar